Agenus | AGEN - Operating Expenses


Agenus reported $19.81M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Agenus USD 19.81M 293.94M Dec/2025
Amgen USD 5.9B 773M Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Celldex Therapeutics USD 87.27M 511.09M Dec/2025
CSL USD 5.7B 2.82B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Glaxosmithkline GBP 9.17B 1.4B Dec/2025
Incyte USD 1.12B 3.53B Dec/2025
Intrexon USD 61.56M 26.1M Jun/2024
J&J USD 17.44B 1.53B Mar/2026
Jiangsu Hengrui CNY 6.12B 180.16M Dec/2025
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
MacroGenics USD 53.32M 13.68M Dec/2025
Merck EUR 4.78B 669M Dec/2025
Merck USD 10.16B 558M Dec/2025
Northwest Biotherapeutics USD -108.65M 8.26M Sep/2025
Novartis USD 9.8B 61M Dec/2025
Novavax USD 126.2M 23.62M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Veracyte USD 116M 7.24M Dec/2025